| Muthu S Krishnan, MD | |
|
1191 Highway Kk, Suite 300, Osage Beach, MO 65065-3510 | |
| (573) 302-4960 | |
| (573) 302-4965 |
| Full Name | Muthu S Krishnan |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 46 Years |
| Location | 1191 Highway Kk, Osage Beach, Missouri |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528089539 | NPI | - | NPPES |
| 1528089539 | Medicaid | MO | |
| P00853879 | Other | MO | RAILROAD MEDICARE |
| 507408201 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | R5P38 (Missouri) | Secondary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | R5P38 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Regional Health System | Osage beach, MO | Hospital |
| Mercy Hospital Lebanon | Lebanon, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lake Regional Medical Management Inc | 3577467323 | 42 |
| Lake Regional Health System | 9133026776 | 81 |
News Archive
TWi Biotechnology, Inc. announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis during urate-lowering therapy. This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Without administering a simple blood test in the first few days after surgery, 85 percent of the heart attacks or injuries patients suffer could be missed, according to a study in the March issue of Anesthesiology.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it priced a public offering of 5,000,000 shares of its common stock at $1.35 per share. Net proceeds from the offering, after underwriting discounts and commissions and expenses, will be approximately $5,697,500. NeoStem has granted the underwriters an option to purchase up to an additional 750,000 shares to cover over-allotments, if any.
Human noroviruses - the leading viral cause of acute diarrhea around the world - have been difficult to study because scientists had not found a way to grow them in the lab.
› Verified 2 days ago
| Entity Name | Lake Regional Medical Management Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639134158 PECOS PAC ID: 3577467323 Enrollment ID: O20031122000076 |
News Archive
TWi Biotechnology, Inc. announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis during urate-lowering therapy. This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Without administering a simple blood test in the first few days after surgery, 85 percent of the heart attacks or injuries patients suffer could be missed, according to a study in the March issue of Anesthesiology.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it priced a public offering of 5,000,000 shares of its common stock at $1.35 per share. Net proceeds from the offering, after underwriting discounts and commissions and expenses, will be approximately $5,697,500. NeoStem has granted the underwriters an option to purchase up to an additional 750,000 shares to cover over-allotments, if any.
Human noroviruses - the leading viral cause of acute diarrhea around the world - have been difficult to study because scientists had not found a way to grow them in the lab.
› Verified 2 days ago
| Entity Name | Lake Regional Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053581454 PECOS PAC ID: 9133026776 Enrollment ID: O20070511000147 |
News Archive
TWi Biotechnology, Inc. announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis during urate-lowering therapy. This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Without administering a simple blood test in the first few days after surgery, 85 percent of the heart attacks or injuries patients suffer could be missed, according to a study in the March issue of Anesthesiology.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it priced a public offering of 5,000,000 shares of its common stock at $1.35 per share. Net proceeds from the offering, after underwriting discounts and commissions and expenses, will be approximately $5,697,500. NeoStem has granted the underwriters an option to purchase up to an additional 750,000 shares to cover over-allotments, if any.
Human noroviruses - the leading viral cause of acute diarrhea around the world - have been difficult to study because scientists had not found a way to grow them in the lab.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Muthu S Krishnan, MD Po Box 1500, Osage Beach, MO 65065-1500 Ph: () - | Muthu S Krishnan, MD 1191 Highway Kk, Suite 300, Osage Beach, MO 65065-3510 Ph: (573) 302-4960 |
News Archive
TWi Biotechnology, Inc. announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis during urate-lowering therapy. This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Without administering a simple blood test in the first few days after surgery, 85 percent of the heart attacks or injuries patients suffer could be missed, according to a study in the March issue of Anesthesiology.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it priced a public offering of 5,000,000 shares of its common stock at $1.35 per share. Net proceeds from the offering, after underwriting discounts and commissions and expenses, will be approximately $5,697,500. NeoStem has granted the underwriters an option to purchase up to an additional 750,000 shares to cover over-allotments, if any.
Human noroviruses - the leading viral cause of acute diarrhea around the world - have been difficult to study because scientists had not found a way to grow them in the lab.
› Verified 2 days ago
James V Vest, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 54 Hospital Dr, Suite 205, Osage Beach, MO 65065 Phone: 573-302-3199 Fax: 573-302-3198 | |
Mohammad Zubair Malik, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 54 Hospital Dr, Osage Beach, MO 65065 Phone: 573-348-8000 | |
Dr. Wendy G Schmitz, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 54 Hospital Dr, Osage Beach, MO 65065 Phone: 573-302-2287 Fax: 573-302-2241 | |
Dr. Kevin Gerard Byrne, D.O. Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 1029 Nichols Rd Ste 201, Osage Beach, MO 65065 Phone: 573-302-7138 Fax: 573-302-7123 | |
Rachandeep Singh, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 54 Hospital Dr, Suite 225, Osage Beach, MO 65065 Phone: 573-302-2762 Fax: 573-302-2268 | |
Dr. Miriam B. Borden, M.D. Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 1075 Nichols Rd, Osage Beach, MO 65065 Phone: 573-302-2828 Fax: 573-302-2830 |